Latest Recruitment News

Syntara Limited has successfully completed Phase 1a trials for its topical anti-fibrotic drug SNT-9465, demonstrating dose-dependent target engagement and safety, and is now progressing to an innovative Phase 1b study in hypertrophic scars.

Fleetwood Limited has announced the immediate departure of CEO Bruce Nicholson, with Chair John Klepec stepping in as interim CEO while a search for a permanent replacement begins.

Belararox Ltd announces the immediate resignation of founding Managing Director Arvind Misra, with Chairman Neil Warburton stepping in as interim leader during the search for a new executive director.

Close the Loop Limited reports stronger Q1 FY26 revenue and EBITDA, boosted by strategic asset sales and operational improvements, while navigating key board and CFO departures.

Tasmea Limited has announced the acquisition of WorkPac Group for up to A$60.7 million, significantly enhancing its workforce solutions capabilities and positioning the company for growth amid Australia's skilled labour shortages.

Tasmea Limited has entered a conditional agreement to acquire WorkPac Group for up to $60.7 million, aiming to enhance its workforce solutions and specialist trade services. The deal is expected to be accretive to earnings and strategically expand Tasmea’s footprint across Australia.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

Tryptamine Therapeutics has enrolled its second patient in a pioneering clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with first dosing scheduled for December and results expected early next year.

Meteoric Resources has successfully completed wet commissioning of its pilot plant in Brazil, marking a key milestone towards rare earth production at the Caldeira Project. First Mixed Rare Earth Carbonate output is expected early December, supporting ongoing feasibility studies and offtake partnerships.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Xamble Group reports a revenue rebound to A$1.7 million in Q3 2025 alongside narrowing EBITDA losses, reflecting early gains from its transformation strategy and technology investments.

Artrya Limited has expanded its SAPPHIRE clinical study with Ascension, one of the largest US non-profit health systems, joining as the fourth major participant. This move strengthens the study’s reach and advances the evaluation of Artrya’s AI-powered Salix platform for coronary artery disease detection.